Tibotec wins marketing authorization for HIV drug in EU
Intelence is said to be the first new non-nucleoside reverse transcriptase inhibitor to be introduced in approximately 10 years. Also known as TMC125, Intelence will be marketed in
Rocket Pharmaceuticals has entered into a credit facility agreement of up to $150m with Hercules Capital to support the ongoing development of its cardiovascular portfolio.